Literature DB >> 17295209

Radiation-induced PARP activation is enhanced through EGFR-ERK signaling.

Michael P Hagan1, Adly Yacoub, Paul Dent.   

Abstract

We examined the impact of EGFR-ERK signaling on poly (ADP-ribose) polymerase (PARP) activation following ionizing irradiation of human prostate cancer (PCa) cell lines displaying marked differences in ERK dependence. PARP activation was indicated by the appearance of polyADP-ribose, the incorporation of P32-labelled NADH, and by cellular NADH. EGFR-ERK signaling was manipulated through ligand activation or signal interruption using the tyrphostin AG1478, or MEK inhibitor PD 184352. EGF activation of ERK prior to irradiation was associated with a marked increase in PARP activation and decreased survival in both cell lines. Prior inactivation of PARP protected both cell lines from the initial decrease in NAD+ and improved the survival of LNCaP cells following combined EGF and IR treatment. MEK inhibitor PD 184352 also reduced PARP activation and improved LNCaP survival following EGF and IR treatment. These data imply that PARP activation following exposure to ionizing radiation is enhanced through EGFR-ERK signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17295209     DOI: 10.1002/jcb.21253

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

Review 1.  The development of MDA-7/IL-24 as a cancer therapeutic.

Authors:  Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Xiang-Yang Wang; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zhao-zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej S Lesniak; Steven Grant; David T Curiel; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2010-08-21       Impact factor: 12.310

Review 2.  MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.

Authors:  Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zhao-Zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej Lesniak; Steven Grant; David T Curiel; Paul B Fisher
Journal:  Anticancer Drugs       Date:  2010-09       Impact factor: 2.248

Review 3.  CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

Authors:  Paul Dent; Yong Tang; Adly Yacoub; Yun Dai; Paul B Fisher; Steven Grant
Journal:  Mol Interv       Date:  2011-04

4.  Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.

Authors:  Clint Mitchell; Margaret Park; Patrick Eulitt; Chen Yang; Adly Yacoub; Paul Dent
Journal:  Mol Pharmacol       Date:  2010-08-09       Impact factor: 4.436

5.  The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway.

Authors:  Prashanthi Javvadi; Andrew T Segan; Stephen W Tuttle; Constantinos Koumenis
Journal:  Mol Pharmacol       Date:  2008-02-05       Impact factor: 4.436

6.  Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.

Authors:  Zhimin Zhang; Xiaojuan Lian; Wei Xie; Jin Quan; Maojun Liao; Yan Wu; Zhen-Zhou Yang; Ge Wang
Journal:  Sci Rep       Date:  2020-12-01       Impact factor: 4.379

7.  Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells.

Authors:  Guofeng He; Xiaoke Di; Jingjing Yan; Caiqiang Zhu; Xinchen Sun; Shu Zhang
Journal:  Cancer Sci       Date:  2018-10-22       Impact factor: 6.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.